Catherine Bollard, MD, Pediatric Hematology & Oncology, Washington, DC

CatherineBollardMD

Pediatric Hematology & Oncology Washington, DC

Professor, Pediatrics and Microbiology, Immunology and Tropical Medicine The George Washington University Director- Program for Cell Enhancement and Technologies for Immunotherapy Children's National Health System and Chief, Division of Allergy and Immunology CNHS

Dr. Bollard is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bollard's full profile

Already have an account?

Education & Training

  • University of Otago School of MedicineMD, Immunology, 2000 - 2005
  • Registrar - HematologyFRCPA, Hematology, 1997 - 2002
  • Registrar- PediatricsFRACP, Pediatrics, 1995 - 2002
  • University of Otago School of Medicine
    University of Otago School of MedicineClass of 1991

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2013 - 2022
  • TX State Medical License
    TX State Medical License 2004 - 2014
  • Royal Australian College of PhysicansPediatrics and Child Health Division
  • Royal College of Pathologists of AustraliaHematology and Immunology

Awards, Honors, & Recognition

  • Induction into the Henry Kunkel Society 2014
  • Basi Science Award European Group for Blood and Marrow Transplantation (EBMT), 2011
  • Induction to American Society of Clinical Investigation (ASCI) 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy  
    Kris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature
  • EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation  
    Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
  • Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204  
    Shalini Shenoy, K Scott Baker, Elizabeth O Stenger, Mary Eapen, Carl Allen, Lauri Burroughs, Philip Roehrs, Catherine M Bollard, Rabi Hanna, Jeffrey R Andolina, James ..., Blood
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH
    Catherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Identifying Novel Immunodominant Epitopes within Human Parainfluenza Virus-3 Matrix Protein
    Catherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Ultra low-dose il-2 mediated expansion of regulatory T cells as GVHD prophylaxis for recipients of allogeneic hematopoietic stem cells blood transplantation.
    Catherine Bollard 1,*,Alana Kennedy-Nasser 2,A. John Barrett 3,Sawa Ito 3,Eric Yvon 4,Robert Krance 2,Kathryn Leung 2,Helen E. Heslop 2,Malcolm K. Brenner2, Poster Presentation, EBMT; Bone Marrow Transplant, Milan, Italy, 1/31/2014
  • Join now to see all

Lectures

  • Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Meet the Blood Editors 
    60th American Society of Hematology Annual Meeting - 12/3/2018
  • Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Other

Press Mentions

  • COVID-19 Fighting T-cells Could Help Protect Vulnerable People
    COVID-19 Fighting T-cells Could Help Protect Vulnerable PeopleOctober 27th, 2020
  • Kymriah Treatment Available at Children’s National Health System
    Kymriah Treatment Available at Children’s National Health SystemApril 16th, 2019
  • Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to Its Board of Directors
    Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to Its Board of DirectorsApril 2nd, 2019
  • Join now to see all

Grant Support

  • Anti-Viral And Antileukemic T-Cell Therapy As Prophylaxis After HSCTNational Heart, Lung, And Blood Institute2011
  • Clinical Trial: The Administration Of Neomycin Resistance Gene Marked EBV SpeciNational Center For Research Resources2011
  • Clinical Trial: Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes ForNational Center For Research Resources2011
  • Adoptive Transfer Of Cord Blood T Cells To Prevent And Treat CMV And AdenovirusNational Center For Research Resources2011
  • Improving Cord Blood TransplantationNational Cancer Institute2011
  • Enhancing Treg Immune Reconstitution After Stem Cell TransplantNational Cancer Institute2011
  • Administration Of Tgf-B Resistant Lmp2a-Specific Cytotoxic T-Lymphocytes To PNational Center For Research Resources2010–2011
  • Clinical Trial: Virus Specific Cytotoxic T-Lymphocytes For The Prophylaxis Of CMNational Center For Research Resources2008–2011
  • Clinical Trial: Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For ENational Center For Research Resources2008–2010
  • Clinical Trial: Administration Of Virus-Specific Cytotoxic T-Lymphocytes For TheNational Center For Research Resources2008–2010
  • Clinical Trial: Administration Of Neomycin Resistance Gene Marked EBV Specific CNational Center For Research Resources2008–2009
  • Clinical Trial: Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes FollowNational Center For Research Resources2008
  • Administration Of Virus-Specific Cytotoxic T-Lymphocytes For The ProphylaxisNational Center For Research Resources2007
  • Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes Following CD45 AntiNational Center For Research Resources2006–2007
  • Virus Specific Cytotoxic T-Lymphocytes For The Prophylaxis Of CMVNational Center For Research Resources2005–2007
  • Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For EBV Pos LymphomaNational Center For Research Resources2005–2007
  • Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes Following CD45National Center For Research Resources2005
  • Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For EBV Pos. LymphomaNational Center For Research Resources2004